BR112018016171A2 - biomarcadores para tb - Google Patents

biomarcadores para tb

Info

Publication number
BR112018016171A2
BR112018016171A2 BR112018016171A BR112018016171A BR112018016171A2 BR 112018016171 A2 BR112018016171 A2 BR 112018016171A2 BR 112018016171 A BR112018016171 A BR 112018016171A BR 112018016171 A BR112018016171 A BR 112018016171A BR 112018016171 A2 BR112018016171 A2 BR 112018016171A2
Authority
BR
Brazil
Prior art keywords
value
decile
sample
individual
biomarker
Prior art date
Application number
BR112018016171A
Other languages
English (en)
Inventor
Kampmann Beate
Julian Hoggart Clive
Togun Toyin
Original Assignee
Imperial Innovations Ltd
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd, Medical Res Council filed Critical Imperial Innovations Ltd
Publication of BR112018016171A2 publication Critical patent/BR112018016171A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)

Abstract

a invenção se refere a um método para o diagnóstico de tb em um indivíduo, o método compreendendo (a) fornecer uma amostra do dito indivíduo, a dita amostra sendo selecionada do grupo que consiste em: sangue, soro e plasma; (b) determinar a concentração na dita amostra dos seguintes biomarcadores: il-1ra, il6, il-7, il-8, il-12p70, fgf-básico, ip-10, e vegf; (c) converter cada concentração de biomarcador determinada em (b) em um valor em decil; e (d) converter cada valor de decil em presença ou ausência binária, pela comparação dos valores de decil de (c) com os seguintes valores específicos de ponto de corte de quantil, em que um valor de decil que combine ou exceda o valor específico do ponto de corte do quantil é convertido na presença binária do biomarcador e um valor de decil menor do que o valor específico do ponto de corte do quantil é convertido na ausência binária do biomarcador; em que a detecção da presença de cada um dos biomarcadores indica que o indivíduo tem tb. a invenção também se refere a usos, kits e dispositivos.
BR112018016171A 2016-02-09 2017-02-03 biomarcadores para tb BR112018016171A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1602305.3A GB201602305D0 (en) 2016-02-09 2016-02-09 TB Biomarkers
PCT/GB2017/050272 WO2017137727A1 (en) 2016-02-09 2017-02-03 Tb biomarkers

Publications (1)

Publication Number Publication Date
BR112018016171A2 true BR112018016171A2 (pt) 2019-01-22

Family

ID=55642029

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016171A BR112018016171A2 (pt) 2016-02-09 2017-02-03 biomarcadores para tb

Country Status (12)

Country Link
US (1) US20190062812A1 (pt)
EP (1) EP3414572B1 (pt)
JP (1) JP2019510206A (pt)
CN (1) CN108779493A (pt)
AU (1) AU2017218546A1 (pt)
BR (1) BR112018016171A2 (pt)
CA (1) CA3013119A1 (pt)
ES (1) ES2805056T3 (pt)
GB (1) GB201602305D0 (pt)
RU (1) RU2756314C2 (pt)
WO (1) WO2017137727A1 (pt)
ZA (1) ZA201804709B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10830760B2 (en) 2017-12-20 2020-11-10 General Electric Company Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058958A1 (en) * 1998-05-14 1999-11-18 Luminex Corporation Diode laser based measurement apparatus
AU2008318690B2 (en) * 2007-10-29 2015-08-13 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
MX2012001716A (es) * 2009-08-14 2012-04-02 Genentech Inc Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
WO2011047033A2 (en) * 2009-10-13 2011-04-21 The Johns Hopkins University Biomarker for identification of melanoma tumor cells
ITRM20100411A1 (it) * 2010-07-23 2012-01-24 Massimo Amicosante Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino.
EP2836608A4 (en) * 2012-04-13 2016-02-24 Somalogic Inc TUBERCULOSIS BIOMARKERS AND USES THEREOF
GB201213567D0 (en) 2012-07-31 2012-09-12 Proteinlogic Ltd Biomarkers
GB201316524D0 (en) 2013-09-17 2013-10-30 Medical Res Council Biomarkers
CN104020297B (zh) * 2014-06-10 2016-12-07 上海交通大学医学院 用于结核分枝杆菌感染检测及临床治疗效果监测的试剂盒及其用途

Also Published As

Publication number Publication date
WO2017137727A1 (en) 2017-08-17
RU2018132056A (ru) 2020-03-11
GB201602305D0 (en) 2016-03-23
RU2018132056A3 (pt) 2020-03-26
CN108779493A (zh) 2018-11-09
US20190062812A1 (en) 2019-02-28
EP3414572B1 (en) 2020-04-22
EP3414572A1 (en) 2018-12-19
AU2017218546A1 (en) 2018-08-02
ES2805056T3 (es) 2021-02-10
JP2019510206A (ja) 2019-04-11
RU2756314C2 (ru) 2021-09-29
ZA201804709B (en) 2020-10-28
CA3013119A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
BR112014007214A8 (pt) Método para determinar a probabilidade de que um indivíduo tenha risco elevado de um evento cardiovascular, método para avaliação do risco de um evento cardiovascular futuro e método implementado por computador para avaliação do risco de um evento cardiovascular
MX2018015704A (es) Control de fluidos.
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
BR112018002040A2 (pt) controle de uma nuvem de dispositivo
BR112014021897A2 (pt) nova fusão fgfr3
BR112016017155A2 (pt) Sistema e dispositivo para geração com alto rendimento de gotículas combinatoriais e métodos de uso
BR112016029634A2 (pt) kit, dispositivo e método para a detecção de câncer de fígado
BR112016029583A2 (pt) ?kit ou dispositivo para a detecção de câncer esofágico e método de detecção?
BR112015023012A2 (pt) titulador automático
BR112016016249A2 (pt) Métodos de análise imunocromatográfica, dispositivo de análise imunocromatográfica e kit
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
AR102037A1 (es) Procesador y método para el procesamiento de una señal de audio por el uso del análisis truncado o las porciones de solapamiento de la ventana de síntesis
MX360479B (es) Anticuerpos contra microbioma, factores de estres y marcadores de mastocitos como marcadores de diagnostico para ibs.
BR112017008654A2 (pt) detector de malária
BR112018067990A2 (pt) cromogranina a como um marcador para câncer de bexiga
BR112016002668A2 (pt) métodos e kits para prognosticar o risco de ter uma doença ou evento cardiovasculares
BR112017022724A2 (pt) planta de milho tolerante a herbicida dbn9858 e sequência de nucleotídeos e método para detectar a mesma
CO2018001917A2 (es) Método de detección de virus causante de enfermedades respiratorias por virus respiratorio sincitial y metapneumovirus humano
WO2016198833A3 (en) Methods for analysing a urine sample
BR112018016171A2 (pt) biomarcadores para tb
BR112017004412A2 (pt) método para medir reatividade de fviii
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
BR112015032574A8 (pt) interceptação de erro de sinal transiente para uma medição de analito determinada a partir de um tempo de amostragem especificado derivado de uma característica física detectada da amostra contendo o analito
PL406989A1 (pl) Profil mikro RNA we krwi jako test wykrywania raka płuca

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MEDICAL RESEARCH COUNCIL (GB) ; IP2IPO INNOVATIONS

B25G Requested change of headquarter approved

Owner name: MEDICAL RESEARCH COUNCIL (GB) ; IP2IPO INNOVATIONS

B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: IP2IPO INNOVATIONS LIMITED (GB) ; UNITED KINGDOM RESEARCH AND INNOVATION (GB)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2708 DE 29-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.